Filter Results
Filter Results
General (63) Partnerships (33) Media Advisory (17) New Technologies (4) Acquisitions (3) New Products (3) Financials (2) Ad hoc (1)
2025 (1) 2024 (12) 2023 (12) 2022 (6) 2021 (18) 2020 (20) 2019 (10) 2018 (10) 2017 (8) 2016 (8)
   Loading...
Showing 1‐10 of 105
Media Advisory
08 Oct 2025
Lonza Receives Swissmedic Approval for Highly Potent Biologics Drug Product Filling Line in Stein (CH)
New aseptic state-of-the-art filling line in Stein (CH) designed for biologics and highly potent products, such as antibody-drug conjugates (ADCs), has received Swissmedic...
Media Advisory
20 Nov 2024
​​Lonza Announces First GMP Batch Completion at ​Next-Generation Mammalian Manufacturing Facility in Portsmouth (US)
First GMP batch released at Lonza’s next-generation mammalian manufacturing facility in Portsmouth (US)   State-of-the-art technology supports Lonza’s next-generation mammalian...
News Release
12 Nov 2024
Lonza to Expand Bioconjugation in Visp (CH) with Two Additional Manufacturing Suites
The expansion of bioconjugation capabilities will provide additional manufacturing capacity for launch and commercial supply, addressing growing market demand 2,000m2 of...
Media Advisory
04 Nov 2024
Lonza’s Synaffix Collaborates with BigHat Biosciences on the Development of a Machine Learning-Designed ADC
Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies Collaboration underscores Lonza’s commitment to helping...
News Release
22 Oct 2024
Lonza Extends Collaboration with Major Pharmaceutical Partner for Integrated Commercial Supply of Antibody-Drug Conjugates
Extension of long-term collaboration includes construction of new customer-dedicated bioconjugation capacity in Visp (CH) and commercial antibody supply of a new ADC The...
Media Advisory
15 Oct 2024
Lonza Completes Expansion of New Drug Product Services Facility in Basel (CH)
Expansion adds a new facility to Lonza’s Drug Product Services (DPS) footprint, supporting clinical and commercial projects through additional quality control (QC) and...
News Release
01 Oct 2024
Lonza Completes Acquisition of Large-Scale Biologics Site in Vacaville (US) from Roche
The Vacaville site is one of the largest biologics manufacturing facilities in the world Acquisition extends Lonza’s US Biologics footprint with a significant presence on the...
Media Advisory
26 Sep 2024
Acumen Pharmaceuticals Extends Collaboration with Lonza to Add Drug Product Manufacturing of Sabirnetug for Early Alzheimer’s Disease
Agreement builds upon a successful collaboration supporting the manufacture of sabirnetug (ACU193) drug substance (DS) for clinical studies in Alzheimer’s disease Extension to...
Media Advisory
05 Sep 2024
​​Lonza Completes Expansion of Microbial Manufacturing Facility in Visp (CH) ​
Expansion adds manufacturing capacity for clinical and commercial supply of microbially-produced biologics The facility is now GMP-qualified for manufacturing...
Media Advisory
15 Aug 2024
UK Government Supports Lonza’s Expansion Plans
Lonza has purchased a plot in Thames Valley Park, with a view to relocating and expanding its primary UK-based Biologics site over the next decade This proposed new site would...
1 2 3 4 ... 11 >